Functional mechanism of the enhancement of 5-fluorouracil sensitivity by TUSC4 in colon cancer cells

Oncology Letters

Volumn 10, Issue 6, 2015, Pages 3682-3688

  Liu, Ming Na ^a   Liu, Ai Yun ^a   Pei, Feng Hua ^a   Ma, Xiao ^a   Fan, Yu Jing ^a   Du, Ya Ju ^a   Liu, Bing Rong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Colorectal cancer; PI3K Akt mTOR; TUSC4

Indexed keywords

CASPASE 3; CASPASE 9; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL VIABILITY ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; LENTIVIRINAE; LUCIFERASE ASSAY; PROTEIN EXPRESSION; TUMOR SUPPRESSOR CANDIDATE 4 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84944729105     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3801     Document Type: Article

References (25)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Patel BB and Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: Minireview. Nutr Cancer 61: 842-6, 2009.
3. Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C and Nobre Leitao C: Inhibition of Fas expression by RNAi modulates 5-fluorouracilinduced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta 1772: 40-47, 2007.
4. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL and Pinedo HM: Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36: 916-924, 2000.
5. Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res 60: 6116-6133, 2000.
6. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60: 1949-1960, 2000.
7. Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935, 2002.
8. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, et al: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62: 2715-2720, 2002.
9. Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, Burger H, Stoter G, Brouwer J and Nooter K: Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: A novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol 64: 259-268, 2003.
10. Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard L, Minna JD and Roth JA: The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66: 9682-9690, 2006.
11. Li J, Wang F, Haraldson K, Protopopov A, Duh FM, Geil L, Kuzmin I, Minna JD, Stanbridge E, Braga E, et al: Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res 64: 6438-6443, 2004.
12. Jayachandran G, Ueda K, Wang B, Roth JA and Ji L: NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One 8: e11994, 2010.
13. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet 345: 939-944, 1995.
14. Johnston PG and Kaye S: Capecitabine: A novel agent for the treatment of solid tumors. Anticancer Drugs 12: 639-646, 2001.
15. Zhou BB and Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature 408: 433-439, 2000.
16. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210: 767-776, 2010.
17. Maira SM, Voliva C and Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Exp Opin Ther Targets 12: 223-238, 2008.
18. Ekstrand AI, J�nsson M, Lindblom A, Borg A and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 9: 125-129, 2010.
19. Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82, 2006.
20. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
21. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
22. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, et al: Doseand-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610, 2008.
23. Proud CG: mTORC1 signalling and mRNA translation. Biochem Soc Trans 37: 227-231, 2009.
24. Xu G, Zhang W, Bertram P, Zheng XF and McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24: 893-900, 2004.
25. Armegnol G, Rojo F, Castellvi ĹJ, Iglesias C, Cuatrecasas M, Pons B, Baselga J and Ram�n y Cajal S: 4E-binding protein 1: A key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res 67: 7551-7555, 2007.